Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2− Advanced Breast Cancer From a US Payer Perspective

Everolimus with EXE demonstrated QALY improvements compared with 3 other endocrine monotherapies. Benchmarked by the economic value of other novel cancer therapies, EVE+EXE might be considered a cost-effective option compared with endocrine therapies for HR+/HER2− ABC.